New combo tackles Drug-Resistant liver cancer in small trial
Disease control
Terminated
This study tested a combination of two drugs (lenvatinib and VIC-1911) in 5 adults with advanced liver cancer that no longer responded to lenvatinib alone. The goal was to see if the combo was safe and could slow cancer growth. The trial was terminated early, so results are limit…
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated May 08, 2026 12:04 UTC